International Journal of Molecular Sciences, Volume 23, Issue 5
2022 March-1 - 504 articles
Cover Story: Galectins are soluble β-D-galactoside binding proteins overexpressed in cancerous cells. They modulate tumor progression, influencing the disease outcome. Therefore, the development of potent inhibitors capable of selectively reducing the activity of galectins represents an important strategy for cancer therapy. In this frame, we have rationally designed a novel selenium-containing diglycosylated compound, featuring the presence of a lipophilic benzyl group at both saccharide residues. The relatively high binding affinity of this new compound to the carbohydrate recognition domain of galectin 3 and galectin 9, its good anti-proliferative and antimigration activity towards melanoma cells, as well as its anti-angiogenesis properties, stimulate further studies aimed at its development as an antitumor agent. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.